WO2001019783A1 - Synthesis of [3,5,7]-1h-imidazo[1,5-a]imidazol-2(3h)-one compounds - Google Patents
Synthesis of [3,5,7]-1h-imidazo[1,5-a]imidazol-2(3h)-one compounds Download PDFInfo
- Publication number
- WO2001019783A1 WO2001019783A1 PCT/US2000/025054 US0025054W WO0119783A1 WO 2001019783 A1 WO2001019783 A1 WO 2001019783A1 US 0025054 W US0025054 W US 0025054W WO 0119783 A1 WO0119783 A1 WO 0119783A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- val
- acid
- phenyl
- group
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Definitions
- the present invention relates generally to the combinatorial synthesis of [3,5,7] -1H- lmidazo [1 , 5-a] ⁇ m ⁇ dazol-2 (3H) -one derivatives. More specifically, the invention provides novel [3,5,7]- lH-imidazo [1 , 5-a] ⁇ m ⁇ dazol-2 (3H) -one compounds as well as novel combinatorial libraries comprised of many such compounds, and methods of synthesizing the libraries .
- the process of discovering new therapeutically active compounds for a given indication involves the screening of all compounds from available compound collections. From the compounds tested one or more structure (s) is selected as a promising lead. A large number of related analogs are then synthesized to develop a structure- activity relation-ship and select one or more optimal compounds. With traditional one-at-a-time synthesis and biological testing of analogs, this optimization process is long and labor intensive.
- Peptides have been, and remain, attractive targets for drug discovery. Their high affinities and specificities toward biological receptors as well as the ease with which large peptide libraries can be combmatorially synthesized make them attractive drug targets.
- the screening of peptide libraries has led to the identification of many biologically-active lead compounds.
- the therapeutic application of peptides is limited by their poor stability and bioavailability in vivo . Therefore, there is a need to synthesize and screen compounds that can maintain high affinity and specificity toward biological receptors, while exhibiting improved pharmacological properties relative to peptides.
- 2-Nitroimidazole (azomycin) is a naturally occurring antibiotic and some synthetic nitroimidazoles are active against intestinal infections (Reviews: Nitroimidazoles; Chemistry; Pharmacology and Clinical Applications, eds . A. Breccia, B. Cavalleri, and G. E. Adams, Plenum Press, New York, 1982; J. H. Boyer, Nitrazoles, VCH, Deerfield Beach, Florida, 1986) .
- Imidazole-containing moieties are found in many biologically active compounds and are known to have useful therapeutic implications.
- the invention provides a rapid approach for combinatorial synthesis and screening of individual compounds and libraries of [3 , 5 , 7] -IH-imidazo [1 , 5- a] ⁇ m ⁇ dazol-2 (3H) -one compounds.
- the present invention further provides libraries and individual compounds and their pharmaceutically-acceptable salts of Formula I.
- the present invention also relates to the preparation of synthetic combinatorial libraries of organic compounds and their pharmaceutically- acceptable salts of Formula I, wherein R 1 , R 2 and R 3 have the meanings provided below.
- the present invention has several benefits and advantages.
- One benefit is the provision of a new synthesis for bicyclic [3 , 5 , 7] -IH-imidazo [1 , 5- a] ⁇ m ⁇ dazol-2 (3H) -one compounds.
- the present invention provides a large array of diverse [3,5,7]- lH-imidazo [1 , 5-a] imidazol-2 (3H) -one compounds that can be screened for biological activity, and as described below, are biologically active.
- An advantage of the invention is that individual compounds can be prepared or libraries containing a plurality of compounds can be prepared.
- Another benefit of the invention is that the yield of bicyclic compound produced is relatively great compared to that obtained in prior syntheses of the parental compound.
- the present invention relates to the preparation and use of synthetic combinatorial libraries and individual compounds of a [3,5,7] -1H- imidazo [1 , 5-a] imidazol-2 (3H) -one also referred to as a imidazo-imidizol-one that correspond in structure to Formula I, and their pharmaceutically-acceptable salts :
- R 1 and R 2 are independently selected from the group consisting of a hydrogen atom (hydrido) , C 1 -C 10 alkyl, C 1 -C 10 substituted alkyl, C7-C 16 phenylalkyl, C 7 -C]_g substituted phenylalkyl, phenyl, substituted phenyl, C3-C7 cycloalkyl, and a C3-C7 substituted cycloalkyl group.
- a hydrogen atom (hydrido) C 1 -C 10 alkyl, C 1 -C 10 substituted alkyl, C7-C 16 phenylalkyl, C 7 -C]_g substituted phenylalkyl, phenyl, substituted phenyl, C3-C7 cycloalkyl, and a C3-C7 substituted cycloalkyl group.
- R3 is selected from the group consisting of a hydrido, C]_-C]_Q alkyl, C]_-C]_Q substituted alkyl, c 2" c 10 alkenyl, C2-C]_o substituted alkenyl, C2-C10 alkynyl, C2-C10 substituted alkynyl, C3-C 7 substituted cycloalkyl, phenyl, C 7 -C ⁇ _g phenylalkyl, c 7" c 1 6 phenylalkenyl, C- -C ⁇ phenylalkenyl and a C 7 - C ] _g substituted phenylalkenyl group.
- R 1 and R 2 are independently selected from the group consisting of a hydrido, methyl, benzyl, 2- butyl, N,N-dimethylaminobutyl, N-methylaminobutyl, N- methyl -N-benzylaminobutyl , 2 -methylpropyl , methylsulfinylethyl , methylthioethyl , N,N- dimethylaminoethyl , N,N-dimethylaminopropyl , N ,N ,N - trimethylguanidinopropyl , N ,N ,N -tribenzyl- guanidinopropyl, N ,N -dibenzylguanidinopropyl, N - methylguanidinopropyl , hydroxy ethyl , 1 -hydroxyethyl , 2 -propyl, N-methyl-3 -indolylmethyl
- R3 is selected from the group consisting of a 1 -phenyl - 1 -cyclopropyl , 1-phenylbutyl , 2- phenylbutyl , 3 -fluorobenzyl , 3-bromobenzyl , , ⁇ , ⁇ - trifluoro-m-xylyl , p-xylyl, 4-fluorobenzyl , 3- methoxybenzyl , 4 -bromobenzyl , 4-methoxybenzyl, 4- ethoxybenzyl , 4 -isobutyl - ⁇ -methyl -benzyl , 3,4- dichlorobenzyl , 3 , 5-bis- (trifluoromethyl) -benzyl , 2- (3 , 4-dimethoxyphenyl) -ethyl , 4-biphenylmethyl , ⁇ - methyl-styryl , 2 - (trifluoromethyl) -styryl ,
- the R groups are those as immediately defined above.
- the stereochemistry of the chiral R 1 group can independently be in the R or S configuration, or a mixture of the two.
- the R 1 group can be the side chain substituent of the ⁇ -carbon of various amino acids.
- the amino acids can be in the L-or D-configuration, resulting in the same R group varying only in its stereochemistry.
- the R ⁇ group is usually illustrated bonded to the bicyclic ring by a wavy line .
- a compound of Formula I can exist in two tautomeric forms; i.e., in the keto or enol forms. Those two tautomeric forms are illustrated in Formula IA, below.
- a contemplated compound of Formula I is usually depicted and discussed as being in the keto form (imidazo-imidizol-one) with the understanding that both keto and enol forms are present in equilibrium.
- C ⁇ _-C ] _o alkyl denotes a straight or branched chain radical such as a methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, amyl , tert-amyl, hexyl , heptyl , decyl group and the like.
- the term “lower alkyl” denotes a C1-C 4 alkyl group.
- a preferred "C ] _-C ⁇ _o alkyl” group is a methyl group.
- C2-C_Q alkenyl denotes a radical such as a vinyl, allyl, 2-butenyl, 3-butenyl, 2- pentenyl, 3 -pentenyl, 4 -pentenyl, 2-hexenyl, 3- hexenyl , 4-hexenyl, 5-hexenyl, 2-heptenyl, 3- heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl and a 2- decenyl group and the like, as well as dienes and trienes of straight and branched chains containing up to ten carbon atoms and at least one carbon-to-carbon (ethylenic) double bond.
- C2-C]_o alkynyl denotes a radical such as ethynyl, propynyl , butynyl , pentynyl , hexynyl , heptynyl , decynyl and the like, as well as di- and t ⁇ ynes of straight and branched chains containing up to ten carbon atoms and at least one carbon-to-carbon (acetylenic) triple bond.
- C 1 -C 10 substituted alkyl "C 2 -
- C]_Q substituted alkenyl and "C2-C10 substituted alkenyl” denote that the above C ] _-C]_Q alkyl group and C2 ⁇ C ] _o alkenyl and alkynyl groups are substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, C3-C7 cycloalkyl, C3-C7 substituted cycloalkyl, naphthyl, substituted naphthyl, adamantyl , abietyl , thiofuranyl , mdolyl , substituted mdolyl, ammo, protected ammo, (monosubstituted) ammo, protected (monosubstituted) ammo, (disubstituted) ammo, guanidmo, (monosubstituted) guanidmo, (disubstituted) guanidmo
- Examples of the above substituted alkyl groups include the cyanomethyl , nitromethyl, chloromethyl , hydroxymethyl , tetrahydro- pyranyloxymethyl , t ⁇ tyloxymethyl , propionyloxymethyl , ammomethyl , carboxymethyl , allyloxycarbonylmethyl , allylcarbonyl -ammomethyl , carbamoyloxymethyl , methoxymethyl , ethoxy ethyl , t- butoxymethyl , acetoxymethyl , chloromethyl, bromomethyl , lodomethyl, 6 -hydroxy-hexyl , 2,4- dichloro (n-butyl) , 2 -ammo (isopropyl) , 2- carbamoyloxyethyl chloroethyl, bromoethyl, fluoroethyl, lodoethyl, chloropropyl , bromopropyl ,
- C]_-C]_Q alkyl, C2 ⁇ C_o alkenyl, C2"C ] _ Q alkynyl, C]_-C]_Q substituted alkyl, C2 ⁇ C]_o substituted alkenyl, or C2-C 10 substituted alkynyl are more preferably C1-C7 or C2-C 7 , respectively, and more preferably, C ⁇ -Cg or C2 ⁇ Cg as is appropriate for unsaturated substituents.
- C 1 -C alkoxy denotes groups that are ether groups containing up to four carbon atoms such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy and like groups.
- a preferred C1-C 4 alkoxy group is methoxy.
- C1-C acyloxy denotes a carboxy group-containing substituent containing up seven carbon atoms such as formyloxy, acetoxy, propanoyloxy, butanoyloxy, pentanoyloxy, hexanoyloxy, heptanoyloxy, benzoyloxy and the like.
- C1-C7 acyl encompasses groups such as formyl , acetyl , propionoyl, butyroyl, pentanoyl, hexanoyl, heptanoyl, benzoyl and the like.
- C3-C7 cycloalkyl includes the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl rings.
- C3-C7 substituted cycloalkyl indicates an above cycloalkyl ring substituted by a halogen, hydroxy, protected hydroxy, phenyl, substituted phenyl, heterocycle, substituted heterocycle, C ] _-C ⁇ _o alkyl, C1-C 4 alkoxy, carboxy, protected carboxy, ammo, or protected ammo.
- C5-C 7 cycloalkenyl indicates a substituent that is itself a 1-, 2-, or 3 -substituted cyclopentenyl ring, a 1-, 2- , 3- or 4- substituted cyclohexenyl ring or a 1-, 2-, 3-, 4- or 5 -substituted cycloheptenyl ring, whereas the term “substituted C3-C 7 cycloalkenyl" denotes the above
- heterocycle denotes an optionally substituted 5- membered or 6-membered ring that has 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, m particular nitrogen either alone or m conjunction with sulfur or oxygen ring atoms.
- heteroatoms such as oxygen, sulfur and/or nitrogen, m particular nitrogen either alone or m conjunction with sulfur or oxygen ring atoms.
- Preferred heterocyclic rings include pyridmo, py ⁇ midmo, and pyraz o, furano, and thiofurano rings.
- the heterocyles can be substituted or unsubstituted as for example, with such substituents as those described m relation to substituted phenyl or substituted naphthyl .
- the term "C 7 -C 1 g phenylalkyl" or "C 7 -C 16 aralkyl” denotes a C]_-C ] _Q alkyl group substituted at any position by a phenyl ring.
- Examples of such a group include benzyl, 2 -phenylethyl , 3 -phenyl (n-prop- 1-yl) , 4 -phenyl (hex- 1-yl) , 3-phenyl (n-am-2-yl) , 3- phenyl (sec-butyl ) , and the like.
- a preferred C 7 -C ] _ phenylalkyl group is the benzyl group.
- C 7 -C]_g substituted phenylalkyl denotes an above C7 ⁇ C]_ phenylalkyl group substituted on the C_-C_Q alkyl portion with one or more, and preferably one or two, groups selected from the group consisting of a halogen, hydroxy, protected hydroxy, keto, C2-C3 cyclic ketal phenyl, amino, protected amino, C1-C 7 acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carbamoyloxy, cyano, N- (methyl - sulfonylamino) or C1-C4 alkoxy group, whose phenyl group portion can be substituted with 1 or 2 groups selected from the group consisting of a halogen, hydroxy, protected hydroxy, nitro, C]_-C]_o alkyl, C ⁇ - Cg substituted alkyl, C1-C 4 alkoxy, carboxy, protected carboxy, carboxymethyl
- C7-C ] _g substituted phenylalkyl examples include groups such as 2-phenyl-l- chloroethyl, 2- (4-methoxyphenyl) eth-l-yl , 2,6- dihydroxy-4 -phenyl (n-hex-2 -yl) , 5 -cyano-3 -methoxy-2 - phenyl (n-pent-3 -yl ) , 3- (2 , 6-d ⁇ methylphenyl ) n-prop-1- yl , 4-chloro-3 -ammobenzyl , 6- (4-methoxyphenyl) -3- carboxy (n-hex-1-yl) , 5- (4 -ammomethyl -phenyl) -3- (ammomethyl) (n-pent-2-yl) , 5-phenyl-3 -keto- (n-pent- 1-yl), 4- (4-ammophenyl) -4- (I .4
- C7-C_ phenylalkenyl denotes a
- a preferred C -C ] _g substituted phenylalkenyl is 3- (4-n ⁇ trophenyl) -2 - propenyl .
- substituted phenyl specifies a phenyl group substituted at one or more positions, preferably at one or two positions, with moieties selected from the group consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C ] _-C ] _ Q alkyl, C]_-C]_Q substituted alkyl, C1-C4 alkoxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, ammo, protected anilmo,
- substituted phenyl include a mono- or di (halo) phenyl group such as 4-chlorophenyl , 2,6- dichlorophenyl , 2 , 5-d ⁇ chlorophenyl , 3,4- dichlorophenyl , 3-chlorophenyl , 3 -bro ophenyl , 4- bromophenyl , 3 , 4 -dibromophenyl , 3-chloro-4- fluorophenyl , 2 -fluorophenyl and the like; a mono or di (hydroxy) phenyl groups such as 4-hydroxyphenyl , 3- hydroxyphenyl , 2 , 4-d ⁇ hydroxyphenyl , the protected hydroxy derivatives thereof and the like; a nitrophenyl group such as 3- or 4 -nitrophenyl , a cyanophenyl group for example, 4-cyanophenyl; a mono- or di (halo) phenyl group such as 4-chlor
- substituted phenyl represents disubstituted phenyl groups wherem the substituents are different.
- 3 -methyl -4 -hydroxyphenyl 3-chloro-4- hydroxyphenyl , 2 -methoxy-4-bromophenyl , 4 -ethyl -2- hydroxyphenyl , 3 -hydroxy-4 -nitrophenyl , 2 -hydroxy- 4- chlorophenyl and the like are contemplated.
- substituted naphthyl specifies a naphthyl group substituted with one or more, and preferably one or two moieties selected from the group consisting of a halogen, hydroxy, protected hydroxy, cyano, nitro, C ⁇ -C ⁇ Q alkyl, C1-C alkoxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl , hydroxymethyl , protected hydroxymethyl, ammo, protected ammo, (monosubstituted) ammo, protected (monosubstituted) ammo, (disubstituted) ammo trifluoromethyl, or a N- (methylsulfonylamino) group.
- substituted naphthyl include 2- (methoxy) naphthyl and 4- (methoxy) naphthyl .
- substituted mdolyl specifies a mdolyl group substituted, either at the nitrogen or carbon, or both, with one or more, and preferably one or two, moieties selected from the group consisting of a halogen, hydroxy, protected hydroxy, cyano, nitro, C]_-C ⁇ o alkyl, C]_-C]_o substituted alkyl, C]_-C]_Q alkenyl, C ⁇ - - ⁇ phenylalkyl, C7-C]_ substituted phenylalkyl, C ⁇ -Cg alkoxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, ammo, protected ammo, monosubstituted ammo, or a disubstituted ammo group.
- substituted mdolyl includes such groups as 6-fluoro, 5-fluoro, 5-bromo, 5-hydroxy, 5 -methyl, 6 -methyl, 7 -methyl, 1 -methyl, 1- ethyl , 1 -benzyl, 1-napthylmethyl , and the like.
- An example of a disubstituted mdolyl is l-methyl-5- methyl mdolyl .
- halo and halogen refer to the fluoro, chloro, bromo, or iodo groups.
- (monosubstituted) ammo refers to an ammo group with one substituent selected from the group consisting of phenyl, substituted phenyl, C ] _-
- ammo (monosubstituted) ammo can additionally have an ammo-protecting group as encompassed by the term
- (disubstituted) ammo refers to am o groups with two substituents selected from the group consisting of phenyl, substituted phenyl, C ] _-
- and “ (trisubstituted) - guanidmo” are used to mean that a guanidmo group is substituted with one, two, or three substituents, respectively.
- the substituents can be any of those as defined above m relation to (monosubstituted) - ammo and (disubstituted) ammo and, where more than one substituent is present, the substituents can be the same or different.
- (monosubstituted) lmidizol-one imidazole, "(disubstituted) lmidizol-one imidazole.” and "(trisubstituted) lmidizol-one imidazole” mean compounds which the lmidizol-one imidazole group is substituted with one, two, or three substituents, respectively.
- the substituents can be any of those as defined above in relation to a (monosubstituted) - amino or (disubstituted) amino group and where more than one substituent is present.
- the substituents can be the same or different.
- amino-protecting group refers to one or more selectively removable substituents on the amino group commonly employed to block or protect the amino functionality.
- protected (monosubstituted) amino means there is an amino-protecting group on the monosubstituted amino nitrogen atom.
- protected carboxamide means there is an amino-protecting group present replacing the proton of the amido nitrogen so that di-N-alkylation.
- amino-protecting groups include the formyl ("For") group, the trityl group (Trt), the phthalimido group, the trichloroacetyl group, the chloroacetyl, bromoacetyl, and iodoacetyl groups.
- Urethane blocking groups such as t-butoxy- carbonyl ("Boc"), 2- (4-biphenylyl) propyl (2 ) - oxycarbonyl (“Bpoc”), 2 -phenylpropyl (2) oxycarbonyl ("Poc”), 2- (4-xenyl) -isopropoxycarbonyl , 1,1- diphenylethyl (1) oxycarbonyl , 1,1- diphenylpropyl (1) oxycarbonyl , 2- (3 , 5-dimethoxyphenyl) propyl (2) oxycarbonyl ("Ddz”), 2- (p-5-toluyl) propyl - (2 ) oxycarbonyl , cyclo-pentanyloxycarbonyl , 1- methylcyclopentanyl -oxycarbonyl , eyelohexanyloxycarbonyl , 1 -methyl - cyclohexanyloxycarbonyl , 2 -methylcyclohexanyloxy
- amino-protecting group employed is usually not critical so long as the derivatized amino group is stable to the conditions of the subsequent reactions and can be removed at the appropriate point without disrupting the remainder of the compound.
- Preferred amino-protecting groups are Boc and Fmoc .
- protected ammo defines an ammo group substituted with an ammo-protectmg group discussed above.
- carboxy-protectmg group refers to one of the ester derivatives of the carboxylic acid group commonly employed to block or protect the carboxylic acid group while reactions are carried out on other functional groups on the compound.
- carboxylic acid protecting groups include 4-n ⁇ trobenzyl , 4-methoxybenzyl, 3 , 4-d ⁇ methoxybenzyl , 2 , 4 -dimethoxybenzyl , 2,4, 6-tr ⁇ methoxybenzyl , 2,4, 6-tr ⁇ methylbenzyl , pentamethylbenzyl , 3 , 4-methylene-d ⁇ oxybenzyl , benzhydryl, 4 , 4 ' -methoxyt ⁇ tyl , 4, 4 ',4''- trimethoxytrityl, 2 -phenylprop-2 -yl , trimethylsilyl, t-butyldimethylsilyl , 2,2,2 -t ⁇ chloroethyl
- hydroxy-protecting group refers to readily cleavable groups bonded to hydroxyl groups, such as the tetrahydropyranyl, 2-methoxyprop- 2-yl, 1-ethoxyeth-l-yl , methoxymethyl , ⁇ -methoxy- ethoxymethyl , methylthiomethyl , t-butyl, t-amyl, trityl, 4-methoxytr ⁇ tyl , 4 , 4 ' -dimethoxyt ⁇ tyl , 4 , 4 ', 4" -trimethoxytrityl , benzyl, allyl, trimethylsilyl, (t-butyl) dimethylsilyl and 2,2,2- t ⁇ chloroethoxycarbonyl groups, and the like.
- the species of hydroxy-protectmg groups is also usually not critical so long as the derivatized hydroxyl group is stable to the conditions of subsequent reaction (s) and can be removed at the
- C 1 -C 4 alkylthio refers to sulfide groups such as methylthio, ethylthio, n-propylthio, isopropylthio, -butylthio, t-butylthio and like groups.
- C1-C4 alkylsulfoxide indicates sulfoxide groups such as methylsulfoxide, ethylsulfoxide, -propylsulfoxide, iso-propyl-sulfoxide, n-butylsulfoxide, sec- butylsulfoxide, and the like.
- C1-C4 alkylsulfonyl encompasses groups such as methylsulfonyl , ethylsulfonyl , n-propylsulfonyl , 1sopropylsulfonyl , ⁇ -butylsulfonyl , t-butylsulfonyl , and the like.
- Phenylthio, phenyl sulfoxide, and phenylsulfonyl compounds are known m the art and these have their art-recognized definitions.
- substituted phenylthio substituted phenyl sulfoxide
- substituted phenylsulfonyl is meant that the phenyl can be substituted as described above m relation to "substituted phenyl.”
- cyclic C2 ⁇ C ] _o alkylene defines a cyclic group bonded ("fused") to the phenyl radical.
- the cyclic group can be saturated or contain one or two double bonds.
- the cyclic group can have one or two methylene groups replaced by one or two oxygen, nitrogen or sulfur atoms.
- the cyclic alkylene or heteroalkylene group can be substituted once or twice by substituents selected from the group consisting of hydroxy, pro- tected-hydroxy, carboxy, protected-carboxy, keto, ketal, C ] _-C4 alkoxycarbonyl, C]_-C4 alkanoyl, C ] _-C ] _o alkyl, carbamoyl, C1-C4 alkoxy, C1-C4, alkylthio, C ] _- C4 alkylsulfoxide, C1-C alkylsulfonyl , halo, amino, protected-amino, hydroxymethyl and a protected- hydroxymethyl group .
- a cyclic alkylene or heteroalkylene group fused onto the benzene radical can contain two to ten ring members, but it preferably contains four to six members.
- saturated cyclic groups include a bicyclic ring system that is a 2,3- dihydroindanyl or a tetralin ring.
- the cyclic groups are unsaturated, examples occur when the resultant bicyclic ring system is a naphthyl ring or indanyl .
- cyclic group that can be fused to a phenyl radical that has two oxygen atoms and that is fully saturated is dioxanyl .
- fused cyclic groups that each contain one oxygen atom and one or two double bonds occur when the phenyl ring is fused to a furyl , pyranyl , dihydrofuryl or dihydropyranyl ring.
- Cyclic groups that each have one nitrogen atom and contain one or two double more double bonds are illustrated where the phenyl is fused to a pyridino or pyrano ring.
- An example of a fused ring system having one nitrogen and two phenyl radicals is a carbozyl group.
- Examples of cyclic groups that each have one sulfur atom and contain one or two double bonds occur where the benzene ring is fused to a thieno, thiopyrano, dihydrothieno, or dihydrothiopyrano ring.
- Examples of cyclic groups that contain two heteroatoms selected from sulfur and nitrogen and one or two double bonds occur where the phenyl ring is fused to a thiazolo, isothiazolo, dihydrothiazolo or dihydroisothiazolo ring.
- Examples of cyclic groups that contain two heteroatoms selected from oxygen and nitrogen and one or two double bonds occur where the benzene ring is fused to an oxazole, isoxazole, dihydroxazole or dihydroisoxazole ring.
- Examples of cyclic groups that contain two nitrogen heteroatoms and one or two double bonds occur where the benzene ring is fused to a pyrazolo, lmidazolo, dihydropyrazolo or dihydroimidazolo ring.
- Examples of cyclic groups that each have one nitrogen atom and contain one or two double more double bonds occur when the phenyl is fused to a pyridmo or pyrano ring.
- An example of a fused ring system having one nitrogen and two phenyl radicals is a carbozyl group.
- Examples of cyclic groups that each have one sulfur atom and contain one or two double bonds occur when the phenyl is fused to a thieno, thiopyrano, dihydrothieno, or dihydrothiopyrano ring .
- Examples of cyclic groups that contain two heteroatoms selected from sulfur and nitrogen and one or two double bonds occur when the phenyl ring is fused to a thiazolo, isothiazolo, dihydrothiazolo or dihydroisothiazolo r ng.
- Examples of cyclic groups that contain two heteroatoms selected from oxygen and nitrogen and one or two double bonds occur when the benzene ring, is fused to an oxazolo, isoxazolo, dihydroox-azolo or dihydroisoxazolo ring.
- Examples of cyclic groups which contain two nitrogen heteroatoms and one or two double bonds occur when the benzene ring is fused to a pyrazolo, Imidazolo, dihydropyrazolo or dihydroimidazolo ring.
- a pharmaceutical composition for treating infections, pa , or other indications treatable by a contemplated imidazo-imidazol-one is administered to a subject m need of the medication at dosage levels of about 0.7 to about 7000 mg per day, and preferably about 1 to about 500 mg per day, for a normal human adult of approximately 70 kg of body weight. This broadly translates into a dosage of about 0.01 to about 100 mg/kg of body weight per day of an lmidizo- lmidazol-one compound of Formula I as active ingredient.
- the specific dosages employed, however, can be varied depending upon the requirements of the patient, the severity of the condition being treated, and the activity of the compound being employed. The determination of optimum dosages for a particular situation is withm the skill of the art.
- One or more of the lmidizo-imidazol-one compounds of Formula I can be present as a pharmaceutically-acceptable salt.
- pharmaceutically-acceptable salt encompasses those salts that form with the carboxylate anions or ammonium cations and include salts formed with the organic and inorganic cations and anions discussed below. Furthermore, the term includes salts that form by standard acid-base reactions with basic groups (such as ammo groups) and organic or inorganic acids.
- Such acids include hydrochloric, sulfuric, phosphoric, acetic, succmic, citric lactic, maleic, fumaric, palmitic, cholic, pamoic, mucic, D-glutamic, d-camphoric, gluta ⁇ c, phthalic, tartaric, lau ⁇ cc, stea ⁇ c, salicyclic, methanesulfonic, benzenesulfonic , sorbic, picric, benzoic, cmnamic, and like acids.
- organic or inorganic cation refers to counterions for the carboxylate anion of a carboxylate salt.
- the counter- ions are chosen from the alkali and alkaline earth metals, (such as lithium, sodium, potassium, barium and calcium) : ammonium; and the organic cations such as (dibenzylammonium, benzylammonium, 2 -hydroxymethyl - ammonium, bis (2 -hydroxyethyl) ammonium, phenyl - ethylbenzyl ammonium, dibebenzylethylenediammoniurn, and like cations) .
- cations encompassed by the above term include the protonated form of procame, qumme and N-methylglucosamme, and the protonated forms of basic ammo acids such as glycme, ornithme, histidine, phenylglyc e, lysme and argmme .
- any zwitterionic form of the instant compounds formed by a carboxylic acid and an ammo group is referred to by this term.
- a preferred cation for the carboxylate anion is the sodium cation.
- a compound of Formula I can also be present as a solvate and hydrate. Thus, these compounds can crystallize with, for example, waters of hydration, or one, a number of, or any fraction thereof of molecules of the mother liquor solvent. The solvates and hydrates of such compounds are included withm the scope of this invention.
- One or more of the contemplated compounds can be m the biologically active ester form, such as the non-toxic, metabolically-labile ester-form. Such ester forms induce increased blood levels and prolong the efficacy of the corresponding non-esterified forms of the compounds .
- Ester groups that can be used include the lower alkoxymethyl groups (C 1 -C 4 alkoxymethyl ) for example, methoxymethyl , ethoxymethyl , isopropoxymethyl and the like; the (C1-C ) alkoxyethyl groups, for example methoxyethyl , ethoxyethyl , propxyethyl , iso-propoxyethyl , and the like, the 2 -oxo-1 , 3 -dioxolen-4 -ylmethyl groups such as 5-methyl-2 -oxo-1 , 3 -dioxolen-4 -ylmethyl , 5-phenyl- 2 -oxo-1 , 3 -dioxolen-4 -ylmethyl , and the like, the C ] _-
- C3 alkylthiomethyl groups for example methylthio- methyl , ethylthiomethyl, isopropylthiomethyl, and the like
- the acyloxymethyl groups for example pivaloyloxymethyl , pivaloyloxyethyl , ⁇ -acetoxymethyl , and the like, the ethoxycarbonyl -1 -methyl group, the ⁇ -acetoxyethyl , the 3-phthalidyl or 5 , 6-dimethyl- phtalidyl groups, the 1- (C1-C4 alkyloxycarbonyloxy) - ethyl groups such as the 1- (ethoxycarbonyloxy) ethyl group, and the 1-(C_-C4 alkylaminocarbonyloxy) ethyl groups such as the 1-methylaminocarbonyloxyethyl group .
- inert, pharmaceutically acceptable carriers are used.
- the pharmaceutical carrier can be either solid or liquid.
- Solid form preparations include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories.
- a solid carrier can be one or more substances that can also act as diluents, flavoring agents, solubilizers , lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
- the carrier is generally a finely divided solid that is m a mixture with the finely divided active component.
- the active compound is mixed with the carrier having the necessary binding properties m suitable proportions and compacted m the shape and size desired.
- a low-meltmg wax such as a mixture of fatty acid glyce ⁇ des and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient-sized molds and allowed to cool and solidify.
- Powders and tablets preferably contain between about 5% to about 70% by weight of the active ingredient.
- Suitable carriers include, for example, magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-meltmg wax, cocoa butter and the like.
- a pharmaceutical composition can include the formulation of the active compound with encapsulating material as a carrier providing a capsule m which the active component (with or without other carriers) is surrounded by a carrier, which is thus m association with it.
- cachets are also included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
- Liquid pharmaceutical compositions include, for example, solutions suitable for oral or parenteral administration, or suspensions, and emulsions suitable for oral administration.
- Sterile water solutions of the active component or sterile solutions of the active component m solvents comprising water, ethanol, or propylene glycol are examples of liquid compositions suitable for parenteral administration.
- Sterile solutions can be prepared by dissolving the active component m the desired solvent system, and then passing the resulting solution through a membrane filter to sterilize it or, alternatively, by dissolving the sterile compound m a previously sterilized solvent under sterile conditions .
- Aqueous solutions for oral administration can be prepared by dissolving the active compound m water and adding suitable flavorants, coloring agents, stabilizers, and thickening agents as desired.
- Aqueous suspensions for oral use can be made by dispersing the finely divided active component m water together with a viscous material such as natural or synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
- the pharmaceutical composition is m unit dosage form.
- the composition is divided into unit doses containing appropriate quantities of the active urea.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparation, for example, packeted tablets, capsules, and powders in vials or ampules.
- the unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms .
- a chemical or combinatorial "library” is an intentionally created collection of a plurality of structurally similar, but different molecules.
- structurally similar it is meant that the constituent compounds of a library have the same ring structure; i.e., a bicyclic imidizo- imidazol-one ring, and at least two positions at which substituents are bonded to the ring structure.
- the member compounds of the library also have the same substitution pattern of substituent groups; i.e., that the at least two substituents be bonded to the same ring positions in each member compound.
- the molecule members of the library are different in that each member has at least one different substituent group from the other members of the library.
- a library can contain two to thousands or millions of member compounds.
- a particular library can also be comprised of members whose substituent groups are all different from each other.
- the shared ring structure contains substituent groups at a plurality of positions
- a library can be prepared in which the member molecules contain different groups at each position.
- a plurality of sub-libraries or sets can also be prepared m which a first set has a first substituent that is held constant for all of the members (is present m all members) of the set, whereas the groups at the other substituent positions are different and constitute a mixture of groups at each substituent position.
- a second set of that plurality has a second, different, first substituent, and the same mixture of different groups at the other substituent positions.
- a third set of that plurality has a third, different first substituent, and the same mixture of different groups at the other substituent positions, and so on until one decides to stop making sets with different first substituents.
- Such set pluralities of structurally similar, but different compounds are also often referred to as libraries of libraries, and are particularly useful m ascertaining which compound or compounds of a library are active m an assay of choice.
- a library can be prepared by the synthetic means discussed below or otherwise herein and screened for biological activity m a variety of formats (e.g. libraries of soluble molecules). Libraries of compounds can be attached to resin beads, silica chips or other solid supports) . The libraries can be screened m any variety of assays, such as those detailed below as well as others useful for assessing the biological activity of lmidazo- lmidazol-ones .
- the libraries typically contain at least one active compound and are generally prepared such that the compounds are equimolar quantities.
- the nonsupport -bound library mixtures prepared herein were screened m solution radio- receptor inhibition assays described m detail hereinafter. Deconvolution of highly active mixtures can then be carried out by iterative, or positional scanning methods. These techniques, the iterative approach or the positional scanning approach, can be utilized for finding other active compounds with the libraries of the present invention using any one of the below-described assays or others well known the art .
- sub- libra ⁇ es are made defining only one variable substituent with each set of sub-libraries and all possible sub-libraries with each single variable substituent defined (and all other possibilities at all of the other variable positions) is made and tested. From the instant description one skilled m the art can synthesize libraries wherem two fixed substituent positions are defined at a time. From the assaying of each single-variable defined library, the optimum substituent at that position is determined, pointing to the optimum or at least a series of compounds having a maximum of the desired biological activity.
- the number of sub- libra ⁇ es for compounds with a single substituent position defined is the number of different substituents desired at that position, and the number of all the compounds m each sub-library is the product of the number of substituents at each of the other variables.
- ammo acids can be used with the present invention as described above to prepare a vast array of bicyclic [3 , 5 , 7] -IH-imidazo [1 , 5-a] - ⁇ m ⁇ dazol-2 (3H) -one with different R 1 , R 2 and R 3 groups. As described above, thirty-three first ammo acids were coupled to the resm, which ammo acids provide the R ⁇ substituent group.
- the thirty-three am o acids included Ala, Phe, Gly, His (DNP) , lie, Lys(CBZ), Leu, Met, Arg(Tos), Nva, Ser(Bzl), Thr(Bzl), Val, Tyr(CHO), Tyr(BrZ), Nle, Cha, ala, phe, his (DNP), lie, lys (CBZ) , leu, met, arg(Tos), ser(Bzl), thr(Bzl), val, trp(CHO), tyr(BrZ), nle, nva , cha .
- Another set or sub-library of 33 compounds was prepared by reacting a single ammo acid (valme) with the resm to provide one R 1 group. After removal of the BOC protecting group, each of the above 33 ammo acids was then separately coupled to provide 33 resm-l ked peptides with the same R 1 group and one of the 33 different R 2 groups. On removing the second BOC group, a single carboxylic acid (acetic acid) was bonded to the free ammo group to provide a single R 3 group for the resm-lmked peptides. Theses compounds were also cyclized to form compounds of Formula I, and cleaved from the resm.
- a single ammo acid (valme) was coupled to the resm to provide a single R 1 group, the BOC group was removed and a second ammo acid (valme) was coupled to provide a single R 2 group and form a dipeptide.
- the dipeptide was separately reacted with each of the 92 carboxylic acids listed Table 2, below, to provide 92 different R 3 groups.
- the acylated peptides were thereafter cyclized, cleaved from the solid support resm and recovered. Assays using those compounds are discussed hereinafter.
- Phenylglycine Phg A variety of carboxylic acids can also be used in the acylation step of the reaction of Scheme 1, thereby providing a wide array of substituents at the R 3 position of the bicyclic [3,5,7] -1H- imidazo [1 , 5-a] imidazol-2 (3H) -one .
- Ninety-two carboxylic acids were used in preparing the [3,5,7]- 1H- imidazo [1 , 5-a] imidazol-2 (3H) -one libraries .
- the ninety-two R 3 groups were provided by the following carboxylic acids:
- Val Val 3 4-D ⁇ chloro- 365 .11 366 .11 366 .2 phenylacetic
- Val Val 3- (3,4- 371 .22 372 .22 372 .2
- 4b 2 X H NMR (500 MHz,CD 3 OD) ⁇ 4.85-4.95 (m, IH) , 2.60 (s, 3H) , 2.54-2.59 (m, IH) , 2.23 (s, IH) , 1.25- 1.26 (d, 3H) , 0.89-0.90 (d, 3H) ; HRMS (FAB) m/z 193.1214 found (M] + , 193.1215 calculated for C 10 H 15 N 3 O. 4b 3 : ⁇ rl NMR (500 MHz,CD 3 OD) ⁇ 7.15-7.41 (m, 5H) ,
- rat brain membranes and the receptor binding assay were carried out as described m Dooley et al . , Life Sci . , 52:1509(1993).
- Each tube m the screening assay contained 0.08 mg of compound mixture per milliliter, 0.5 mL of membrane suspension (0.1 mg of protein), 7 nM 3 H-labeled DAMGO [specific activity 36 Ci/mmol, obtained from the National Institute on Drug Abuse (NIDA) repository through Chiron Mimotopes PeptideSystems (San Diego, CA) and 50 mL of peptide mixture m 50 mM T ⁇ s-HCl buffer (pH 7.4). The final volume was 0.65 mL .
- the results of these screenings are shown m the table, below, wherein the "R" groups are as discussed for
- guinea pig cortices and cerebella were homogenized in 40 mL of Buffer A [50 mM Tns-
- Each assay tube contained 0.5 mL of membrane suspension, 3 nm of t ⁇ tiated Compound U69, 593 [ (5a,7a, 8b) - (-) -N-methyl-N- (7- (1- pyrrolidmyl) -1-oxasp ⁇ ro (4,5)dec-8-yl)- benzeneacetamide ; Lahti et al . , European J. Pharmacol . , 109:281-284 (199-85) ] m a total volume of 0.65 mL . Assay tubes were incubated for 2.5 hours a
- Example 1 Where individual reactants are used to provide a particular R group, the procedures of Example 1 are followed. Where mixtures are desired at a particular R group, the protected amino acids or carboxylic acids are provided in mixtures. The mixtures used to provide the various R groups are listed in the table, below, with the relative molar amount of each reactant being listed.
- Boc-L-Ile 1.16 Boc-L- lie 1.16 3 -Fluorophenyl- 0.84 acetic Acid Boc-L- 1.05 Boc-L-Lys (CBZ) 1.05 3 -Bromophenyl - 0.61
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60036955T DE60036955T2 (en) | 1999-09-17 | 2000-09-13 | PREPARATION OF [3,5,7] -1H-IMIDAZO- [1,5-a] IMIDAZOLE-2 (3H) -ONE COMPOUNDS |
CA002383373A CA2383373C (en) | 1999-09-17 | 2000-09-13 | Synthesis of [3,5,7]-1h-imidazo[1,5-a]imidazol-2(3h)-one compounds |
AU73760/00A AU781284B2 (en) | 1999-09-17 | 2000-09-13 | Synthesis of (3,5,7)-1H-imidazo(1,5-a)imidazol-2(3H)-one compounds |
EP00961864A EP1218337B1 (en) | 1999-09-17 | 2000-09-13 | Synthesis of 3,5,7|-1h-imidazo 1,5-a|imidazol-2(3h)-one compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15444399P | 1999-09-17 | 1999-09-17 | |
US60/154,443 | 1999-09-17 | ||
US09/659,370 US6545032B1 (en) | 1999-09-17 | 2000-09-12 | Synthesis of [3,5,7]-H-imidazo[1,5-a] imidazol-2(3H)-one compounds |
US09/659,370 | 2000-09-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001019783A1 true WO2001019783A1 (en) | 2001-03-22 |
Family
ID=26851453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/025054 WO2001019783A1 (en) | 1999-09-17 | 2000-09-13 | Synthesis of [3,5,7]-1h-imidazo[1,5-a]imidazol-2(3h)-one compounds |
Country Status (8)
Country | Link |
---|---|
US (2) | US6545032B1 (en) |
EP (1) | EP1218337B1 (en) |
AT (1) | ATE376993T1 (en) |
AU (1) | AU781284B2 (en) |
CA (1) | CA2383373C (en) |
DE (1) | DE60036955T2 (en) |
ES (1) | ES2295055T3 (en) |
WO (1) | WO2001019783A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050261474A1 (en) * | 2004-05-20 | 2005-11-24 | Mixture Sciences, Inc. | Method of support-based chemical synthesis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0854140A2 (en) * | 1996-12-20 | 1998-07-22 | Hoechst Aktiengesellschaft | Vitronectin receptor antagonists, their production and their use |
EP0854145A2 (en) * | 1996-12-20 | 1998-07-22 | Hoechst Aktiengesellschaft | Vitronectin receptor antagonists, their production and their use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4478845A (en) | 1983-01-19 | 1984-10-23 | E. I. Du Pont De Nemours And Company | Antiinflammatory and/or analgesic imidazoimidazoles |
JPH07119760B2 (en) | 1984-07-24 | 1995-12-20 | コモンウエルス・セ−ラム・ラボラトリ−ズ・コミッション | How to detect or determine a mimotope |
DE69130831T2 (en) | 1990-11-21 | 1999-09-16 | Iterex Pharma Lp | SYNTHESIS OF EQUIMOLAR MIXTURES OF VARIOUS OLIGOMERS, SPECIALLY OLIGOPEPTIDE MIXTURES |
US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
WO1998034113A1 (en) | 1997-02-04 | 1998-08-06 | Trega Biosciences, Inc. | Combinatorial libraries of bicyclic guanidine derivatives and compounds therein |
WO1998041223A1 (en) | 1997-03-20 | 1998-09-24 | The Regents Of The University Of California | N-methyl-d-aspartate receptor channel blockers and method for identifying such |
-
2000
- 2000-09-12 US US09/659,370 patent/US6545032B1/en not_active Expired - Fee Related
- 2000-09-13 ES ES00961864T patent/ES2295055T3/en not_active Expired - Lifetime
- 2000-09-13 WO PCT/US2000/025054 patent/WO2001019783A1/en active IP Right Grant
- 2000-09-13 EP EP00961864A patent/EP1218337B1/en not_active Expired - Lifetime
- 2000-09-13 AT AT00961864T patent/ATE376993T1/en not_active IP Right Cessation
- 2000-09-13 AU AU73760/00A patent/AU781284B2/en not_active Ceased
- 2000-09-13 CA CA002383373A patent/CA2383373C/en not_active Expired - Fee Related
- 2000-09-13 DE DE60036955T patent/DE60036955T2/en not_active Expired - Fee Related
-
2002
- 2002-05-08 US US10/141,439 patent/US6664282B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0854140A2 (en) * | 1996-12-20 | 1998-07-22 | Hoechst Aktiengesellschaft | Vitronectin receptor antagonists, their production and their use |
EP0854145A2 (en) * | 1996-12-20 | 1998-07-22 | Hoechst Aktiengesellschaft | Vitronectin receptor antagonists, their production and their use |
US5990145A (en) * | 1996-12-20 | 1999-11-23 | Hoechst Aktiengesellschaft | Vitronectin receptor antagonists, their preparation and their use |
Non-Patent Citations (3)
Title |
---|
BIRKETT P. ET AL.: "Synthesis and intramolecular cyclisation of 5-aminoimidazolealkanoates and their conversion to purine derivatives", SYNTHESIS, February 1991 (1991-02-01), pages 157 - 159, XP002935760 * |
DATABASE HCAPLUS [online] AMERICAN CHEMICAL SOCIETY, WASHINGTON, D.C.; SUNJIC V. ET AL.: "Reactions of some 1-(carboxy)alkyl nitroimidazole derivatives in polyphosphonic acid", XP002935761, accession no. CAS Database accession no. 1970:100605 * |
J. OF HETEROCYCLIC CHEM., vol. 7, no. 1, 1970, pages 211 - 213 * |
Also Published As
Publication number | Publication date |
---|---|
EP1218337A4 (en) | 2002-09-11 |
US20020193608A1 (en) | 2002-12-19 |
DE60036955T2 (en) | 2008-08-07 |
EP1218337B1 (en) | 2007-10-31 |
CA2383373A1 (en) | 2001-03-22 |
AU781284B2 (en) | 2005-05-12 |
ES2295055T3 (en) | 2008-04-16 |
ATE376993T1 (en) | 2007-11-15 |
EP1218337A1 (en) | 2002-07-03 |
AU7376000A (en) | 2001-04-17 |
CA2383373C (en) | 2008-02-12 |
DE60036955D1 (en) | 2007-12-13 |
US6545032B1 (en) | 2003-04-08 |
US6664282B2 (en) | 2003-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU774270C (en) | Diketodiazacyclic compounds, diazacyclic compounds and combinatorial libraries thereof | |
US5859190A (en) | Combinatorial libraries of hydantoin and thiohydantoin derivatives, methods of making the libraries and compounds therein | |
US5856107A (en) | Combinatorial libraries of imidazol-pyrido-indole and imidazol-pyrido-benzothiophene derivatives, methods of making the libraries and compounds therein | |
US5783577A (en) | Synthesis of quinazolinone libraries and derivatives thereof | |
WO1997010221A1 (en) | Synthesis of quinazolinone libraries | |
JP5222948B2 (en) | Novel compound of reverse turn analogue and its use (3) | |
US5916899A (en) | Isoquinoline derivatives and isoquinoline combinatorial libraries | |
WO2001021634A1 (en) | Benzimidazole derivatives and combinatorial libraries thereof | |
WO1998018781A9 (en) | Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents | |
US5786448A (en) | Combinatorial libraries of cyclic urea and cyclic thiourea derivatives and compounds therein | |
WO2001023887A1 (en) | 2-aminopyridine derivatives and combinatorial libraries thereof | |
US20030171588A1 (en) | 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof | |
US6545032B1 (en) | Synthesis of [3,5,7]-H-imidazo[1,5-a] imidazol-2(3H)-one compounds | |
US6861523B2 (en) | 1,3,5- trisubstituted-1,3,5-triazine-2,4,6-trione compounds and libraries | |
US6359144B1 (en) | Combinatorial libraries of bicyclic guanidine derivatives and compounds therein | |
WO1998034113A1 (en) | Combinatorial libraries of bicyclic guanidine derivatives and compounds therein | |
CA2416654A1 (en) | Bicyclic hydantoin derivatives and combinatorial libraries thereof | |
EP1646633B1 (en) | Beta-strand mimetics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 73760/00 Country of ref document: AU Ref document number: 2383373 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000961864 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000961864 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 73760/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000961864 Country of ref document: EP |